Advocates request that the South African Health Products Regulatory Authority expedite registration of essential medicines for the treatment and prevention of TB in South Africa.
In an open letter sent to the South African Health Products Regulatory Authority (SAHPRA) on 23 August 2018, South African and global civil society partners called attention to the urgent need to register essential medicines for the treatment and prevention of TB in South Africa.
“Namely, we request your attention to 1) marketing approval of, and expedition of further research into, delamanid, an important medicine for treating drug-resistant strains of TB; 2) approval of rifapentine, which allows for dramatic shortening of preventive therapy for TB; and 3) approval of child-friendly formulations of TB medicines, which facilitate dosing and ease the burden of TB treatment on children and those administering treatment alike.”
The signatories requested a response by 5 September 2018.
To download the open letter, click here.